Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine

No licensed vaccine is available for prevention of EBV-associated diseases, and robust, high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed an improved EBV-GFP based neutralization assay for such a vaccine’s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mediterr J Hematol Infect Dis
Autori principali: Liu, Hui, Gemmell, Lorraine, Lin, Rui, Zuo, Fengrong, Balfour, Henry H., Woo, Jennifer C., Hayes, Gregory M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Università Cattolica del Sacro Cuore 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7059750/
https://ncbi.nlm.nih.gov/pubmed/32180911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2020.016
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi